

INVITATION

Biosimilar Antibodies: Examining the Facts and the Clinical Dilemmas

Wednesday,
13 March 2013
14.00 – 15.30

Room 252 A+B

Le Palais des Congrès de Paris
2, Place de la Porte Maillot
75 017 Paris, France

Chair and Moderator

Jos Kosterink, PharmD, PhD
University Medical Center Groningen
Groningen, the Netherlands

Faculty

Timothy Illidge, MD, PhD
The Christie Hospital
Manchester, United Kingdom

Javier Cortés, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain

Target Audience

This educational activity is specifically designed for pharmacists and other healthcare providers interested in biosimilar antibodies.

Learning Objectives


After successful completion of this educational activity, participants should be able to:

- ◆ Discuss the complexities regarding biosimilar antibody development and usage
- ◆ Evaluate the role of monoclonal antibodies in the treatment of lymphoma and breast cancer
- ◆ Analyze major issues of contention regarding biosimilar antibodies, including immunogenicity, extrapolation, traceability, and automatic substitution

18th Congress of the European Association
of Hospital Pharmacists

AGENDA

- 14.00 Welcome and introduction
- 14.05 Biosimilar antibodies: Are we prepared?
Jos Kosterink, PharmD, PhD
- 14.25 Q & A
- 14.30 Case #1: Non-Hodgkin lymphoma: A critical appraisal
of biosimilar anti-CD 20 antibodies
Timothy Illidge, MD, PhD
- 14.50 Q & A
- 14.55 Case #2: Breast cancer: A critical appraisal of biosimilar
anti-HER2 antibodies
Javier Cortés, MD, PhD
- 15.15 Q & A
- 15.20 Take-home messages



This meeting is a prIME Oncology activity.



Support for this educational activity is provided by
F. Hoffmann - La Roche Ltd.

www.prIMEoncology.org

